Skip to main content

Table 2 Demographic information for patients who provided fibroblasts

From: C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice

  Patient Age/Sex Histology KL-6a (U/mL) SP-Db (ng/mL) FVC (L) FEV1.0 (L) TLC (L) DLco (mL/min/mmHg)
With ILD 1 84/M Sq 613 159 2.13 1.76 3.84 6.06
  2 69/M Sq 622 159 3.07 2.23 4.29 8.79
  3 64/M Ad 1129 321 2.77 2.27 4.25 12.0
  4 79/M Sq 599 62.4 2.85 2.14 4.36 9.75
  5 77 M Sq 658 103 2.71 2.21 4.32 12.9
Without ILD 1 81/F Ad NDc NDc 1.95 1.45 3.24 9.84
  2 79/F Sq NDc NDc 2.27 1.76 3.98 12.8
  3 81/M Ad NDc NDc 3.17 2.18 5.39 16.3
  1. Definition of abbreviations:
  2. ILD interstitial lung disease, Sq squamous cell carcinoma, Ad adenocarcinoma, SP-D surfactant protein-D, FVC forced vital capacity, FEV1.0 forced expiratory volume 1.0 (sec), TLC total lung capacity, Dlco diffusing capacity of the lung carbon monoxide
  3. aNormal range of serum KL-6 is <500U/mL
  4. bNormal range of serum SP-D is <110 ng/mL
  5. cThe serum levels of KL-6 and SP-D in the patients without ILD were not examined